SAN DIEGO, CA--(Marketwired - Jul 29, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for the product, EPINEPHRINE INJECTION, USP, 1:1000 (0.3 mg
SAN DIEGO, CA--(Marketwired - Jul 29, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for the product, EPINEPHRINE INJECTION, USP, 1:1000 (0.3 mg
SAN DIEGO, CA--(Marketwired - Jun 6, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced that it will present at the 9 th Annual JMP Securities Healthcare Conference at The Westin New York Grand Central on Wednesday, June 25, 2014. President and CEO, Dr.
SAN DIEGO, CA--(Marketwired - Jun 6, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced that it will present at the 9 th Annual JMP Securities Healthcare Conference at The Westin New York Grand Central on Wednesday, June 25, 2014. President and CEO, Dr.
SAN DIEGO, CA -- (Marketwired) -- 06/04/14 -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced it will present at the LD Micro Invitational Conference today at the Luxe Sunset Boulevard Hotel in Los Angeles. The Company's presentation by Dr.
SAN DIEGO, CA -- (Marketwired) -- 06/04/14 -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced it will present at the LD Micro Invitational Conference today at the Luxe Sunset Boulevard Hotel in Los Angeles. The Company's presentation by Dr.
SAN DIEGO, CA--(Marketwired - May 29, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for its epinephrine pre-filled single dose syringe (PFS) product.
SAN DIEGO, CA--(Marketwired - May 29, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for its epinephrine pre-filled single dose syringe (PFS) product.
SAN DIEGO, CA--(Marketwired - Jan 24, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) announced an important addition to its intellectual property with receipt of a Notice of Allowance of patent claims supporting its cancer immunotherapy portfolio in the United States.
SAN DIEGO, CA--(Marketwired - Jan 24, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) announced an important addition to its intellectual property with receipt of a Notice of Allowance of patent claims supporting its cancer immunotherapy portfolio in the United States.
SAN DIEGO, CA--(Marketwired - Jan 13, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 558,000 shares of common stock at a public offering price of $5.95 per share
SAN DIEGO, CA--(Marketwired - Jan 13, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 558,000 shares of common stock at a public offering price of $5.95 per share
SAN DIEGO, CA--(Marketwired - Jan 7, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) announced today that at a closing held on December 27, 2013, it made a final payment of $7 million to fully acquire from 3M Company and 3M Innovative Properties Company certain intellectual
SAN DIEGO, CA--(Marketwired - Jan 7, 2014) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) announced today that at a closing held on December 27, 2013, it made a final payment of $7 million to fully acquire from 3M Company and 3M Innovative Properties Company certain intellectual
San Diego, California - December 18, 2013 - Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the closing of its previously announced underwritten public offering of 3,720,000 shares of common stock at a public offering price of $5.95 per share.
San Diego, California - December 18, 2013 - Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the closing of its previously announced underwritten public offering of 3,720,000 shares of common stock at a public offering price of $5.95 per share.
SAN DIEGO, CA--(Marketwired - Dec 13, 2013) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced the pricing of an underwritten public offering of 3,720,000 shares of common stock at an offering price of $5.95 per share. The gross proceeds to Adamis from this offering are
SAN DIEGO, CA--(Marketwired - Dec 13, 2013) - Adamis Pharmaceuticals Corporation ( NASDAQ : ADMP ) today announced the pricing of an underwritten public offering of 3,720,000 shares of common stock at an offering price of $5.95 per share. The gross proceeds to Adamis from this offering are
SAN DIEGO, CA--(Marketwired - Nov 20, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ) today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed public offering of common stock and warrants.
SAN DIEGO, CA--(Marketwired - Nov 20, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ) today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed public offering of common stock and warrants.
SAN DIEGO, CA--(Marketwired - Sep 9, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ) today announced that a recently published study conducted by university researchers found that the company's antimicrobial and spermicidal agent, C31G, was effective in treating Herpes
SAN DIEGO, CA--(Marketwired - Sep 9, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ) today announced that a recently published study conducted by university researchers found that the company's antimicrobial and spermicidal agent, C31G, was effective in treating Herpes
SAN DIEGO, CA--(Marketwired - Aug 21, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology
SAN DIEGO, CA--(Marketwired - Aug 21, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology
SAN DIEGO, CA--(Marketwired - Aug 9, 2013) - Adamis Pharmaceuticals Corp. ( OTCQB : ADMP ) ("the Company"), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease,
SAN DIEGO, CA--(Marketwired - Aug 9, 2013) - Adamis Pharmaceuticals Corp. ( OTCQB : ADMP ) ("the Company"), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease,
SAN DIEGO, CA--(Marketwired - Aug 6, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ) announced today that it has entered into an agreement to exclusively license and, with additional payment, fully acquire 3M Company's ( NYSE : MMM ) Taper Dry Powder Inhaler (DPI) technology under
SAN DIEGO, CA--(Marketwired - Aug 6, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ) announced today that it has entered into an agreement to exclusively license and, with additional payment, fully acquire 3M Company's ( NYSE : MMM ) Taper Dry Powder Inhaler (DPI) technology under
SAN DIEGO, CA--(Marketwired - Jul 1, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ) announced today that it has completed a private placement financing transaction pursuant to which it issued senior secured convertible promissory notes and warrants to purchase up to 13,004,316 shares
SAN DIEGO, CA--(Marketwired - Jul 1, 2013) - Adamis Pharmaceuticals Corporation ( OTCQB : ADMP ) announced today that it has completed a private placement financing transaction pursuant to which it issued senior secured convertible promissory notes and warrants to purchase up to 13,004,316 shares
SAN DIEGO , May 3, 2013 /PRNewswire/ -- Dennis J. Carlo, Ph.D., the President and Chief Executive Officer of Adamis Pharmaceuticals Corporation (OTCQB: ADMP), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology
SAN DIEGO , May 3, 2013 /PRNewswire/ -- Dennis J. Carlo, Ph.D., the President and Chief Executive Officer of Adamis Pharmaceuticals Corporation (OTCQB: ADMP), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology
SAN DIEGO , Feb. 28, 2013 /PRNewswire/ -- Adamis Pharmaceuticals Corporation (OTCQB: ADMP), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease,
SAN DIEGO , Feb. 28, 2013 /PRNewswire/ -- Adamis Pharmaceuticals Corporation (OTCQB: ADMP), a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease,
